To include your compound in the COVID-19 Resource Center, submit it here.

CATT: Role reversal on safety

Avastin adverse events higher, but CATT not powered to answer safety questions

Setting aside cost, the real medical debate over the CATT study is centered on safety differences seen in the Avastin bevacizumab and Lucentis ranibuzimab arms.

In previous drug safety controversies, including Avandia rosiglitazone from GlaxoSmithKline plc and the COX-2 inhibitors, academic researchers argued that small increases in risk seen in controlled clinical trials and in epidemiological studies should be taken extremely seriously.

Drug manufacturers argued that imbalances in adverse events in trials should not be considered definitive, particularly in the absence of biological plausibility, and that

Read the full 841 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers